Therapeutic Updates, Announcements and Authorised Prescriber Pathways
This page is dedicated to helping RANZCO Fellows rapidly identify medicine shortages relevant to ophthalmology, find suitable alternatives as indicated by the relevant RANZCO committees, and access information relating to Authorised Prescriber pathways in Australia and New Zealand.
Disclaimer: This information complements but does not replace official information. Always refer to official sources for more detailed advice.
List of ophthalmology drugs on the Pharmaceutical Benefits Scheme
Click here to view a list of drugs, relevant to ophthalmology, available on the Pharmaceutical Benefits Scheme.
Disclaimer: RANZCO has made every effort to ensure the accuracy and completeness of the listed Ophthalmology drugs available on the Pharmaceutical Benefits Scheme (PBS). The list may not reflect changes or updates since Monday 1 December 2025. For the most up to date information please visit this page or contact the RANZCO Policy Team via policy@ranzcodev.dev.nucleoserver.com.
Authorised prescriber forms
Please send all Authorised Prescriber endorsement letter requests to AuthorisedPrescriber@ranzcodev.dev.nucleoserver.com
Note:
In 2021, the Therapeutics Goods Administration (TGA) implemented a change to the Authorised Prescriber scheme to streamline the application process for medicines considered to have an established history of use in Australia. This change removes the requirement for Human Research Ethics Committee (HREC) approval or specialist College endorsement (RANZCO) to be submitted to the TGA in circumstances where you are applying to become an Authorised Prescriber of some medicines with an established history of use.
The list of all medicines with an established history of use is available here.
Additionally, certain drugs can be accessed immediately under the Special Access Scheme (SAS) Category C. This means that you do not need an endorsement letter from the College to support updating your Authorised Prescriber status. You will have to complete the online form via the SAS and AP online system.
Open Consultations
Australia
New Zealand
Proposal relating to funded access to infliximab, etanercept, secukinumab and rituximab – Closes 5pm (New Zealand Standard Time) on Thursday 27 November 2025.
Quick Links
Australia
Therapeutic Goods Administration (TGA)
Pharmaceutical Benefits Scheme (PBS)
Aotearoa New Zealand
Pharmac
Medsafe
